Investment and M&A transaction comps
Healthcare Investment & M&A Transaction Comps
Healthcare services, healthcare IT, medtech, diagnostics, life sciences tools and related healthcare transactions. Pure biotech rows are tracked separately where normal revenue multiples are less meaningful.
| Year | Transactions | Priced | Median EV or valuation / revenue | Median EV or valuation / EBITDA |
|---|---|---|---|---|
| 2026 | 32 | 8 | 6.0x | - |
| 2025 | 3 | 0 | - | - |
| 2022 | 3 | 1 | 4.9x | 17.1x |
| 2021 | 3 | 2 | - | 11.9x |
Sortable transaction comps
Healthcare transaction table
Rows with reported value
1 / 1
Acquisition EV, USD
USD 435M
Investment EV, USD
-
Median EV / revenue
-
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
1 shown of 1 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dersimelagon rights Control | 2026-08-18 | LEO Pharma | USD 435M Consideration | 435 | - | - | Denmark / Japan | Confirmed 3 sources |